Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 12/20 | 0.55 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DHFR | P00374 | 2/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25939429 | 0.85 | DHODH (0.46) | DHODHDPP4DPP8DHFRAKR1C2 | |
| SCHEMBL25939579 | 0.84 | DHODH (0.46) | DHODH | |
| SCHEMBL25939558 | 0.82 | DHODH (0.59) | DHODH | |
| SCHEMBL25939555 | 0.81 | DHODH (0.52) | DHODH | |
| SCHEMBL25939563 | 0.81 | DHODH (0.61) | DHODH | |
| SCHEMBL15973888 | 0.80 | DHODH (0.55) | DHODHDHFRAKR1C2AKR1C1TOP2A | |
| SCHEMBL25939550 | 0.80 | DHODH (0.51) | DHODH | |
| SCHEMBL15973479 | 0.76 | DHODH (0.56) | DHODHDHFR | |
| SCHEMBL25939422 | 0.76 | MCL1 (0.50) | DHODHDPP4DPP8 | |
| SCHEMBL25939538 | 0.72 | DPP4 (0.42) | DHODHDPP4DPP8AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717512-B2 | Methods of use for trisubstituted benzotriazole derivatives | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717512-B2 | Methods of use for trisubstituted benzotriazole derivatives | BRDT, BRPF3, BRD4 | DHODH 441/4885DPP4 2193/4885DPP8 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.